TREAT YOUR ELIGIBLE PATIENTS WITH SIMPLICITY

Extend to Q16 dosing directly after only 3 loading doses in both nAMD and DMO with EYLEA 8 mg

The frequency of monitoring visits should be based on the patient’s status and at the physician’s discretion.

Dosing diagram for illustrative purpose only.

After reaching Q16, patients can be extended to Q20 using an extension method such as T&E*

The frequency of monitoring visits should be based on the patient’s status and at the physician’s discretion.

Dosing diagram for illustrative purpose only.

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.

The recommended dose is 8 mg aflibercept, equivalent to 0.07 mL solution. The posology is the same for the nAMD and DMO indications. The 8 mg dose requires use of the EYLEA 114.3 mg/ml vial.

EYLEA at monthly doses of 8 mg has not been studied for more than 3 consecutive doses.

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).

Abbreviations

DMO, diabetic macular oedema. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q8, every 8 weeks. Q12, every 12 weeks. Q16, every 16 weeks. Q20, every 20 weeks. T&E, treat and extend. VEGF, vascular endothelial growth factor.